Docket No.: HO-P02652US1

AMENDMENTS TO THE CLAIMS

Claims 1-14 are Canceled.

15. (Cancel)

16. (Currently amended) A method of treating a <u>diabetic ulcerwound</u>, other than ophthalmic wounds or gastric or duodenal ulcers, comprising the step of administering to a subject <u>having a diabetic ulcer</u>, other than by buccal administration, a therapeutically effective amount of a lactoferrin composition to result in an improvement or a remediation of a symptom of the diabetic ulcer.

- 17. (Original) The method of claim 16, wherein said lactoferrin composition is administered topically, orally or parenterally.
- 18. (Original) The method of claim 17, wherein said lactoferrin composition is administered orally.
- 19. (Original) The method of claim 18 further comprising administering an antacid in conjunction with said lactoferrin composition.
- 20. (Original) The method of claim 16 further comprising administering a standard wound healing therapy in combination with the lactoferrin composition.
- 21. (Original) The method of claim 16, wherein the administering comprises administering said composition for at least one week to at least twelve weeks.
- 22. (Original) The method of claim 16, wherein the amount of the lactoferrin that is administered is about 0.0001 µg to about 100 g per day.
- 23. (Original) The method of claim 16, wherein said composition is a topical gel, a solution, capsule or a tablet having a lactoferrin concentration of about 0.0001% to about 30%.

55270270.1 -4-

Docket No.: HO-P02652US1

Application No. 10/663,258 Amendment dated Reply to Office Action of

24. (Currently amended) The method of claim 23, wherein said topical gel is composed from a polymer selected from the group of consisting of a vinyl polymer, polysaccharide polymer, glycosaminoglycan polymer, protein polymer, polyoxyethylene-polyoxypropylene polymer, <u>carbomers</u> and acrylamide polymer.

25. (Original) The method of claim 24, wherein the polymer concentration is about 0.5% (w/w) to about 3.0% (w/w) and the polymer has a molecular weight of about 50,000 to about 13,000,000.

26.-51. Canceled

- 52. (New) The method of claim 17, wherein said lactoferrin composition is administered topically.
- 53. (New) The method of claim 17, wherein said lactoferrin composition is administered parenterally.

55270270.1 -5-